小剂量罗红霉素联合多索茶碱治疗支气管扩张的效果  

Effect of low-dose roxithromycin combined with doxofylline in the treatment of bronchiectasis

作　　者：赵媛 宁欣 ZHAO Yuan;NING Xin(Department of Respiratory Medicine,Jinqiu Hospital of Liaoning Province,Shenyang 110000,China)

机构地区：[1]辽宁省金秋医院呼吸内科,110000

出　　处：《中国实用医药》2023年第2期32-35,共4页China Practical Medicine

摘　　要：目的探讨小剂量罗红霉素联合多索茶碱治疗支气管扩张的效果。方法80例支气管扩张患者,采用随机数字表法分为对照组及观察组,每组40例。对照组单用小剂量罗红霉素治疗,观察组行小剂量罗红霉素联合多索茶碱治疗。对比两组患者的肺功能指标[第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气流量峰值(PEF)、FEV1/FVC],临床疗效,24h排痰量及治疗期间急性加重发作次数,不良反应发生率,胸部CT评分、改良呼吸困难指数(mMRC)评分、生活质量评分。结果治疗后,两组患者的FEV1、FVC、PEF、FEV1/FVC均高于本组治疗前,且观察组患者的FEV1、FVC、PEF、FEV1/FVC分别为(2.46±0.54)L、(3.07±0.62)L、(4.95±0.84)L/s、(72.64±10.54)%,高于对照组的(1.92±0.52)L、(2.71±0.58)L、(4.30±0.87)L/s、(63.79±11.25)%,差异具有统计学意义(P<0.05)。观察组患者的总有效率97.50%高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者的24h排痰量均少于本组治疗前,且观察组患者的24h排痰量(6.38±0.72)ml少于对照组的(10.45±1.06)ml,差异具有统计学意义(P<0.05)。观察组患者治疗期间急性加重发作次数(2.11±0.32)次少于对照组的(3.36±0.41)次,差异具有统计学意义(P<0.05)。两组患者的不良反应发生率对比,差异无统计学意义(P>0.05)。治疗后,两组患者的胸部CT评分、mMRC评分低于本组治疗前,生活质量评分高于本组治疗前,且观察组患者的胸部CT评分(5.18±1.03)分、mMRC评分(1.30±0.22)分低于对照组的(6.64±1.10)、(1.70±0.49)分,生活质量评分(75.32±5.46)分高于对照组的(68.78±6.65)分,差异具有统计学意义(P<0.05)。结论支气管扩张患者采用小剂量罗红霉素联合多索茶碱治疗,可大大降低排痰量和急性加重发作次数,促使肺功能得到有效改善,无明显不良反应,兼具可靠性和安全性,值得采纳运用。Objective To discuss the effect of low-dose roxithromycin combined with doxofylline in the treatment of bronchiectasis.Methods A total of 80 patients with bronchiectasis were divided into a control group and an observation group according to random numerical table,with 40 cases in each group.The control group was treated by low-dose roxithromycin alone,and the observation group was treated by lowdose roxithromycin combined with doxorubicin.Both groups were compared in terms of pulmonary function indexes[forced expiratory volume in one second(FEV1),force vital capacity(FVC),peak expiratory flow rate(PEF),FEV1/FVC],clinical efficacy,amount of 24-h sputum excretion,number of acute exacerbations during treatment,incidence of adverse reactions,chest CT score,modified British medical research council(mMRC)score,and quality of life score.Results After treatment,the FEV1,FVC,PEF,FEV1/FVC in both groups were higher than those before treatment in this group;the FEV1,FVC,PEF,FEV1/FVC in the observation group were(2.46±0.54)L,(3.07±0.62)L,(4.95±0.84)L/s,(72.64±10.54)%,which were higher than(1.92±0.52)L,(2.71±0.58)L,(4.30±0.87)L/s,(63.79±11.25)%in the control group;the differences were statistically significant(P<0.05).The total effective rate of patients in the observation group was 97.50%,which was higher than 80.00%in the control group,and the difference was statistically significant(P<0.05).After treatment,the amount of 24-h sputum excretion in both groups was less than that before treatment in this group;the amount of 24-h sputum excretion in the observation group was(6.38±0.72)ml,which was less than(10.45±1.06)ml in the control group;and the differences were statistically significant(P<0.05).The number of acute exacerbations during treatment in the observation group was(2.11±0.32)times,which was less than(3.36±0.41)times in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P

关 键 词：罗红霉素 多索茶碱 支气管扩张 效果 

分 类 号：R562.22[医药卫生—呼吸系统]